Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors.
PubMed 文献 · RMD Open · 2019-02-18
[This corrects the article DOI: 10.1136/rmdopen-2018-000692.].
原文
[This corrects the article DOI: 10.1136/rmdopen-2018-000692.].
来源:RMD Open,查看原文。版权归原作者所有。
引用
- Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open. 2019. PMID: 30886737. doi:10.1136/rmdopen-2018-000692corr1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。